+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Plasminogen Activators - Pipeline Insight, 2021

  • ID: 5310601
  • Clinical Trials
  • March 2021
  • Region: Global
  • 60 Pages
  • DelveInsight

FEATURED COMPANIES

  • Boehringer Ingelheim
  • Cereno Scientific
  • Chiesi Farmaceutici
  • Genentech
  • Supergene
  • Tasly Pharmaceutical
This “Plasminogen activators - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Plasminogen activators pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Plasminogen activators Understanding


Plasminogen activators: Overview


Plasmin is the serine protease responsible for degradation of fibrin. Two forms of the zymogen precursor plasminogen circulate in plasma, the native more abundant form, Glu-plasminogen, and the intermediate form Lys-plasminogen, formed by cleavage of the N-terminal peptide from Glu-plasminogen. The plasminogen activator (PA) system is an extracellular proteolytic enzyme system associated with various physiological and pathophysiological processes. The first-generation plasminogen activators like streptokinase and urokinase are compounds found in nature that lack fibrin selectivity, while second-generation activators including t-PA and scu-PA are natural human proteins that possess some fibrin selectivity and can be produced either by selected human cell cultures or by recombinant DNA methods. The third-generation plasminogen activators are numerous compounds that are in clinical development and possess enhanced properties as a result either of chemical modification or of the application of recombinant DNA technology.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Plasminogen activators R&D. The therapies under development are focused on novel approaches for Plasminogen activators.

Plasminogen activators Emerging Drugs Chapters


This segment of the Plasminogen activators report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Plasminogen activators Emerging Drugs


TMS-007: TMS

TMS-007 is a plasminogen activator based small molecule that is associated with breaking down blood clots, and is believed to inhibit local inflammation at the site of thrombosis. TMS-007 is designed to restore blood flow following acute stroke. TMS-007 is currently being evaluated in a Phase 2 study in Japan, in patients with acute ischemic stroke (AIS).

Recombinant staphylokinase: Supergene

Recombinant staphylokinase is a Plasminogen activators containing Forteplase as the active substance. It is single chain molecule that consists of 138 amino acids. When staphylokinase is added to human plasma containing a fibrin clot, it preferentially reacts with plasmin at the clot surface, forming a plasmin-staphylokinase complex. The drug is in Phase III clinical evaluation for the treatment of pulmonary embolism and stroke.

Plasminogen activators: Therapeutic Assessment


This segment of the report provides insights about the different Plasminogen activators drugs segregated based on following parameters that define the scope of the report, such as:


Major Players working on Plasminogen activators


There are approx. 10+ key companies which are developing the Plasminogen activators. The companies which have their Plasminogen activators drug candidates in the most advanced stage, i.e. Phase III include, Supergene.

Phases


This report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage products (Phase I/II and Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Plasminogen activators pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Plasminogen activators: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Plasminogen activators therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Plasminogen activators drugs.

Plasminogen activators Report Insights

  • Plasminogen activators Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Plasminogen activators Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Scenario and Emerging Therapies:

  • How many companies are developing Plasminogen activators drugs?
  • How many Plasminogen activators drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Plasminogen activators?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Plasminogen activators therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Plasminogen activators and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Genentech
  • TMS
  • Tasly Pharmaceutical
  • Cereno Scientific
  • Supergene
  • Boehringer Ingelheim
  • Chiesi Farmaceutici

Key Products

  • Tenecteplase
  • TMS 007
  • Prourokinase recombinant
  • CS-1
  • Recombinant staphylokinase
  • Alteplase
  • CUSA-081
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Boehringer Ingelheim
  • Cereno Scientific
  • Chiesi Farmaceutici
  • Genentech
  • Supergene
  • Tasly Pharmaceutical

IntroductionExecutive Summary
Plasminogen activators: Overview
  • Structure
  • Mechanism of Action

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Plasminogen activators - Analytical Perspective
In-depth Commercial Assessment
  • Plasminogen activators companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Plasminogen activators Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)
  • Comparative Analysis

Recombinant staphylokinase: Supergene
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

TMS 007: TMS
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

CS-1: Cereno Scientific
  • Product Description
  • Research and Development
  • Product Development Activities

Pre-clinical and Discovery Stage Products
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Plasminogen activators Key CompaniesPlasminogen activators Key ProductsPlasminogen activators- Unmet NeedsPlasminogen activators- Market Drivers and BarriersPlasminogen activators- Future Perspectives and ConclusionPlasminogen activators Analyst ViewsPlasminogen activators Key CompaniesAppendix
List of Tables
Table 1 Total Products for Plasminogen activators
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Plasminogen activators
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Genentech
  • TMS
  • Tasly Pharmaceutical
  • Cereno Scientific
  • Supergene
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
Note: Product cover images may vary from those shown